Navigation Links
GlaxoSmithKline’s Tykerb is to Be Started Earlier in Breast Cancer, Study Find

London: Statistics from a Phase III study has shown that GlaxoSmithKline's Tykerb along with Roche's Xeloda is far better than Xeloda alone in women with HER2// positive advanced breast cancer, where the disease had progressed despite previous therapy involving Herceptin.

Basis the findings, researchers opined that, Tykerb should be checked out for its use during the early treatment of HER2 positive breast cancer.

"Patients with advanced or metastatic HER2 positive breast cancer have limited options once their cancer has progressed on trastuzumab and standard initial chemotherapy regimens. There has been a clear need for alternative treatments to help women with metastatic breast cancer in this advanced setting. Lapatinib combined with capecitabine has demonstrated superior efficacy over capecitabine alone in this group of patients and we look forward to it being made available to women suffering from this devastating disease," said lead investigator Charles Geyer, Director of Breast Medical Oncology at Allegheny General Hospital, Pittsburgh, Pennsylvania, U.S.

Women suffering HER2 positive breast cancer carry an enhanced risk of advancement of disease and death as against women suffering tumors.
'"/>




Page: 1

Related medicine news :

1. GlaxoSmithKline’s Epilepsy Drug given the Green Signal by FD
2. GSK Seeks Permission to Market Breast Cancer Pill Tykerb
3. International Osteoporosis Research Centre To Be Started In India.
4. New Test Can Detect Breast Cancer 8 Years Earlier
5. Earlier the better to start healthy diets
6. Gum Disease Affects Diabetic Children Earlier Than Anticipated
7. Earlier Introduction of Solid Foods in Infants Could Prevent Wheat Allergy
8. Earlier the Cochlear Implants Used Better the Speech
9. Profiling of Cancer Genes May Lead to Earlier Detection Human Cancers
10. Hay Fever Season may Begin Earlier, Warns Experts
11. Diabetes Risk Factors Develop Earlier in Women Than Men
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/26/2017)... ... April 26, 2017 , ... Bioclinica® ... sponsors and CROs to speed clinical development, has released the industry’s only ... Bioclinica AGILE RTSM provides seamless clinical supply forecasting and management together ...
(Date:4/25/2017)... KY (PRWEB) , ... April 25, 2017 , ... ... announce they have signed an agreement to be the preferred physical therapy provider ... injuries and returning them to Derby City CrossFit as quickly and effectively as ...
(Date:4/25/2017)... ... April 25, 2017 , ... A recent report from the ... for the 2015-16 school year across Wisconsin’s public schools, charter schools, and private ... patterns in student test score performance, the report’s limited analyses fail to provide ...
(Date:4/25/2017)... ... 2017 , ... As pharmaceutical companies are held to increasingly ... innovation in drug formulation and manufacturing. CoreRx offers its clients more than ... support of their development and manufacturing goals. , The company was created ...
(Date:4/25/2017)... Scotch Plains, NJ (PRWEB) , ... April 25, 2017 , ... Saad B. Chaudhary, MD ... with the treatment of acute or chronic problems, I focus on preventative care with all ... patient. If you have any questions, always feel free to contact my office and my ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017 Global Surgical Drainage Device ... tubes used to remove excess liquid and air. The ... urine, bile or lymph. Surgical drains are used in ... as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic surgery etc. ... to prevent accumulation of fluid e.g. blood or pus. ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
(Date:4/19/2017)... , April 19, 2017  SARES•REGIS Group ... it is developing at Conejo Spectrum Business Park ... to Atara Biotherapeutics, Inc. , a biopharmaceutical ... and life-threatening diseases that have been underserved by ... T-cell therapies for cancer, autoimmune and infectious disease. ...
Breaking Medicine Technology: